Maraviroc plus Raltegravir
ROCnROL (ANRS 157) Trial
Study Design: ROCnRAL (ANRS 157)

- **Background**: Pilot, phase II, single-arm trial to evaluate capacity of a dual regimen of raltegravir plus maraviroc to maintain viral suppression in virally suppressed adults with HIV who have hyperlipidemia.

- **Inclusion Criteria** (n = 44)
  - Adults
  - On ART for ≥5 years
  - Naïve to INSTIs and maraviroc
  - HIV RNA <200 copies/mL x 24 months and <50 copies/mL for ≥12 months
  - R5 tropism

- **Switch Treatment Arm**
  - Raltegravir 400 mg BID + Maraviroc 300 mg BID
Maraviroc + Raltegravir
ROCnRal (ANRS 157): Result

Week 24 Virologic Response

HIV RNA < 50 copies/ml (%)

79%

Maraviroc + Raltegravir
ROCnRal (ANRS 157): Result

Analysis of Lipids on Dual Therapy (Median time = 19.4 weeks)

Maraviroc + Raltegravir
ROCnRal (ANRS 157): Result

Change in Bone Mineral Density from Baseline (Median interval: 26 wks)

Maraviroc + Raltegravir
ROCnRal (ANRS 157): Conclusions

Conclusions: “In long-term-experienced patients, maraviroc/raltegravir therapy lacks virological robustness despite a benefit in lipid profile and bone density.”

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.